| Author | Publication time | Research type | Mean age (years) | Therapeutic regimen | Median number of prior treatment | Number of patients |
| Dreyling M et al. [9] | 2015 | Cohort | 68 | Ibrutinib | 2 (1 - 9) | 139 |
| Wang ML et al. [4] | 2015 | Cohort | 68 (40 - 84) | Ibrutinib | 3 (1 - 5) | 111 |
| Martin P et al. [12] | 2019 | Cohort | 65 (42 - 81) | Ibrutinib + palbociclib | 1 (1 - 5) | 27 |
| Wang ML et al. [3] | 2015 | Cohort | 67 (45 - 86) | Ibrutinib + rituximab | 3 (1 - 9) | 50 |
| Jerkeman M et al. [13] | 2018 | Cohort | 69 (45–85) | Ibrutinib + lenalidomide + rituximab | 2 (1 - 7) | 50 |
| Martin P et al. [14] | 2019 | Cohort | / | Ibrutinib | 3 (1, 15) | 149 |
| Wang M et al. [10] | 2014 | Cohort | 67.5 (35 - 85) | Ibrutinib | 2 (1 - 8) | 120 |
| Jurczak W et al. [15] | 2013 | Cohort | 68 | Ibrutinib | 3 (-) | 111 |
| Maruyama D et al. [16] | 2019 | Cohort | 72 (55 - 83) | Ibrutinib | 2.5 (1 - 4) | 16 |
| Tam CS et al. [17] | 2018 | Cohort | 68 (47 - 81) | Ibrutinib + venetoclax | 2 (1 - 6) | 24 |
| Sharman JP et al. [18] | 2015 | Cohort | 71 (55 - 80) | Ibrutinib + Ublituximab | 3 (1 - 8) | 15 |
| Tucker D et al. [19] | 2016 | Cohort | 67 (48 - 90) | Ibrutinib | 3 (1 - 6) | 61 |